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Purpose:  Mutations  in  the  SOX2  and  CHX10  genes  have  been  reported  in  patients  with  anophthalmia  and/or
microphthalmia. In this study, we evaluated 34 anophthalmic/microphthalmic patient DNA samples (two sets of siblings
included) for mutations and sequence variants in SOX2 and CHX10.
Methods: Conformational sensitive gel electrophoresis (CSGE) was used for the initial SOX2 and CHX10 screening of
34 affected individuals (two sets of siblings), five unaffected family members, and 80 healthy controls. Patient samples
containing heteroduplexes were selected for sequence analysis. Base pair changes in SOX2 and CHX10 were confirmed
by sequencing bidirectionally in patient samples.
Results: Two novel heterozygous mutations and two sequence variants (one known) in SOX2 were identified in this
cohort. Mutation c.310 G>T (p. Glu104X), found in one patient, was in the region encoding the high mobility group
(HMG) DNA-binding domain and resulted in a change from glutamic acid to a stop codon. The second mutation, noted
in two affected siblings, was a single nucleotide deletion c.549delC (p. Pro184ArgfsX19) in the region encoding the
activation domain, resulting in a frameshift and premature termination of the coding sequence. The shortened protein
products may result in the loss of function. In addition, a novel nucleotide substitution c.*557G>A was identified in the
3′-untranslated  region  in  one  patient.  The  relationship  between  the  nucleotide  change  and  the  protein  function  is
indeterminate. A known single nucleotide polymorphism (c. *469 C>A, SNP rs11915160) was also detected in 2 of the
34 patients. Screening of CHX10 identified two synonymous sequence variants, c.471 C>T (p.Ser157Ser, rs35435463)
and c.579 G>A (p. Gln193Gln, novel SNP), and one non-synonymous sequence variant, c.871 G>A (p. Asp291Asn, novel
SNP). The non-synonymous polymorphism was also present in healthy controls, suggesting non-causality.
Conclusions: These results support the role of SOX2 in ocular development. Loss of SOX2 function results in severe eye
malformation. CHX10 was not implicated with microphthalmia/anophthalmia in our patient cohort.
Anophthalmia  (an  absence  of  eye  structures)  and/or
microphthalmia (an abnormally small eye) are rare disorders
with a prevalence of 0.2–0.4 per 10,000 births in developed
countries [1-3]. One or both eyes are affected in isolation or
as part of other birth defects [4-9]. The disease exhibits diverse
patterns of genetic inheritance, and the severity is variable due
to the genetic heterogeneity of the ocular malformation.
Mutations in several human genes are associated with
anophthalmia and microphthalmia. Among them, mutations
in SOX2 appear to account for most cases [4,10-14]. SOX2,
which is located at chromosome 3q26.3-q27, encodes 317
amino acids that belong to the high-mobility-group (HMG)
DNA-binding protein family. Expressed in embryonic stem
cells and a wide variety of tissues during early development,
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SOX2 plays an important role in cell differentiation and early
organogenesis  [15,16].  In  ocular  tissues,  the  inhibition  of
SOX2 expression in the developing Xenopus retina has been
shown to reduce cell proliferation and allows cells to develop
into non-neuronal cell types [17]. Working in concert with
PAX6, SOX2 regulates downstream target genes such as the
crystalline genes to guide early lens development [18].
Mutations in SOX2 account for approximately 10% of
anophthalmia and microphthalmia cases [4,10,19]. Previously
reported  cases  of  anophthalmia  and  microphthalmia  were
associated  with  SOX2  whole-gene  deletions  or  coding
sequence mutations [4,10-13,19,20]. In this study, a cohort of
34 anophthalmia/microphthalmia patients was screened for
mutations in SOX2. Two novel heterozygous mutations and
two sequence variants (one novel, one known SNP) were
identified in 6 (two siblings) out of 34 patients. This confirms
the importance of SOX2 mutation screening in patients with
anophthalmia/microphthalmia.  In  screening  unaffected
family  members,  we  also  found  an  individual  with  a
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583pathogenic allele suggesting the novel finding that autosomal
dominant SOX2 mutations can be non-penetrant.
As part of our large scale screening campaign, mutation
analysis of CHX10 was also performed. The homeodomain
protein CHX10 has been shown to be essential for ocular
development [21], and autosomal recessive mutations of the
gene have been implicated in microphthalmia in both humans
and  mice  [22-24].  Screening  of  the  same  cohort  of
anophthalmia/microphthalmia  patients  identified  two
synonymous  sequence  variants  in  exon  3  and  one  non-
synonymous  sequence  variant  in  exon  5.  This  non-
synonymous  polymorphism  was  also  present  in  normal
controls. We did not find sequence variants in other exons of
CHX10, suggesting that CHX10 mutations are less frequent in
patients with anophthalmia.
METHODS
Subjects: To identify existing and potentially novel mutations
of  SOX2  and  CHX10  in  a  cohort  of  anophthalmia  and
microphthalmia  patients,  we  undertook  a  candidate  gene
screening approach. We screened 34 affected individuals (two
sets of siblings), five unaffected family members, and 80
healthy controls. Patient demographics are summarized in
Appendix 1. The study was approved by the Institutional
Review Board for Human Subject Research at the Children’s
Hospital of Philadelphia and at the Albert Einstein Medical
Center.  The  study  also  conformed  to  the  tenets  of  the
Declaration of Helsinki. Informed consent was obtained from
all subjects whose blood and DNA samples were used in the
analysis. Peripheral blood samples (10–20 ml) were collected,
and genomic DNA was extracted using the Puregene DNA
isolation kit (Gentra Systems, Minneapolis, MN).
Conformation-sensitive-gel-electrophoresis:  Conformation-
sensitive-gel-electrophoresis  (CSGE)  was  used  for  initial
SOX2  and  CHX10  gene  screenings.  Standard  polymerase
chain reaction (PCR) was performed on genomic DNA of
affected patients, unaffected relatives, and healthy controls to
amplify SOX2 and CHX10 exonic sequences (primer sets are
available  upon  request).  An  additional  120  base  pairs  of
intronic sequences at both the 5′-end and 3′-end were also
included.  PCR  amplification  was  performed  in  a  reaction
volume of 25 μl containing 50 ng of genomic DNA, 200 μM
dNTP, 0.4 μM of each primer pair, 1.5 mM MgCl2, 1X PCR
buffer,  1X  Q-solution,  and  1.25  units  of  Taq  polymerase
(Qiagen, Valencia, CA). A single annealing temperature of
55 °C was used for all primers. PCR products were separated
by electrophoresis in an 8% polyacrylamide gel for detection
of  heteroduplexes  and  homoduplexes.  Patient  samples
containing  heteroduplexes  were  selected  for  sequence
analysis.  Base  pair  changes  in  SOX2  and  CHX10  were
confirmed by sequencing bidirectionally in patient samples.
RESULTS
Of the 34 patients (32 independent probands) analyzed, three
(two siblings) showed novel mutations in coding sequence
and three had two sequence variants in the 3′-untranslated
region (UTR) of SOX2 (Figure 1 and Table 1). Mutation, c.
310 G>T (p. Glu104X), found in one patient, was in the region
encoding the HMG DNA-binding domain and resulted in a
change  from  glutamic  acid  to  a  stop  codon.  The  second
mutation,  noted  in  two  affected  siblings,  was  a  single
nucleotide deletion c.549delC (p. Pro184ArgfsX19) in the
region  encoding  the  activation  domain,  resulting  in  a
frameshift and premature termination of the coding sequence.
In addition, a novel nucleotide substitution, c.*557G>A, was
identified in the 3′-untranslated region in one patient, and a
known single nucleotide polymorphism (c. *469 C>A, SNP
rs11915160)  was  also  detected  in  2  out  of  34  patients
(Appendix 1).
Patient  40A  is  an  eight-year-old  child  with  bilateral
anophthalmia. Clinical features included dilated ventricles
with  ventriculo-peritoneal  shunt  placement  for
hydrocephalus, microcephaly, atrophic optic nerves, chiasm,
posterior  corpus  callosum  and  splenium,  and  abnormal
electroencephalograms with no overt seizures. The patient has
short stature and delayed motor and mental development. He
has an unusual ataxic gait but is independently mobile with a
walker. He has begun to speak in three to four word sentences.
The amplified genomic fragments from the patient (40A)
showed faster and slower migrating products comparing to
that of the wild type observed in samples from the parents
(40B and 40C) and normal controls (C1 and C2) with CSGE
(Figure 2A). The heteroduplexes suggest a mutation in the
fragment. The genomic DNA from this patient was sequenced
bidirectionally. Two alleles were identified (Figure 2B), one
with a wild type allele and one with a nucleotide substitution
at c.310 G>T of the coding sequence, resulting in a nonsense
amino  acid  change  (p.  Glu104X).  The  predicted  shorter
peptide is truncated at the end of the HMG domain, which
results in the deletion of the entire COOH-terminal activation
Figure  1.  SOX2  gene  structure  and  mutations  in  anophthalmia/
microphthalmia. The 5′- and 3′- untranslated regions are shown as
blank boxes, and the coding region is shown as a filled box. The start
(ATG) and the stop (TGA) codons are indicated. Mutations detected
in  this  study  are  indicated.  The  nuclear  targeting  sequence  is
underlined. HMG=high mobility group, G=guanosine, T=thymidine,
C=cytidine,  A=adenosine,  Glu=glutamic  acid,  Pro=proline,
Arg=arginine, X=stop, FS=frameshift.
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585domain  (Figure  2C).  The  mutation,  located  in  the  HMG
domain, is not directly involved in DNA binding based on
NMR-spectroscopy  structure  from  the  Protein  Data  Bank
(PDB).  Both  parents  were  homozygous  for  the  wild  type
allele.
Patient  54A  is  a  nine-year-old  child  with  right
anophthalmia and left microphthalmia. Her clinical features
included  a  right  middle  fossa  arachnoid  cyst  and  partial
absence  of  the  posterior  aspect  of  the  corpus  callosum
including  the  splenium.  She  had  mild  hydrocephalus  and
partial complex seizures. Other abnormalities were growth
and thyroid hormone deficiency, developmental delays, and a
wide-based  ataxic  gait.  She  also  presented  with  facial
Figure 2. Mutation in the SOX2 HMG domain. Genomic DNA from
affected  patients,  unaffected  relatives,  and  healthy  controls  are
amplified by PCR. PCR products are separated by electrophoresis in
an  8%  polyacrylamide  gel  for  detection  of  heteroduplexes  and
homoduplexes.  Genomic  DNA  samples  are  then  sequenced  for
detection of sequence variants. A: Heteroduplexes detected by CSGE
is shown. Lanes C1 and C2 represent the healthy controls; Lane 40A
represents  the  proband;  Lane  40B  represents  the  mother  of  the
proband; and Lane 40C is the father of the proband. Sample from
patient 40A shows heteroduplex comparing to homoduplex observed
in samples from the parents (40B and 40C) and normal controls (C1
and C2). B: Single nucleotide substitution at c.310 G>T of the coding
sequence is identified in patient 40A, but not in the parents (40B and
40C) and normal controls (C1 and C2). C: Mutation at c.310 G>T
results in a nonsense amino acid change at p. Glu104X as illustrated.
HMG=high mobility group.
asymmetry with a beaked nose, small widely-spaced teeth,
and  diastasis  recti.  The  parents  were  unaffected.  CSGE
analysis  showed  three  slower  migrating  product  bands  in
addition to the wild type, indicative of heterozygosity (Figure
3A). The affected sibling of the proband (54H), who was
diagnosed with bilateral anophthalmia by ultrasound in utero,
had two slower migrating bands and the wild type product. An
amniocentesis was performed, and a chromosome study was
that  of  a  normal  female  with  a  46XX  karyotype.  Her
birthweight  of  8  lbs  15  ounces  and  length  of  52  cm  are
appropriate for a term infant. Her newborn hearing screening
test  was  normal.  An  orbital  ultrasound  shortly  after  birth
revealed the absence of globe structures bilaterally. A head
MRI at age of four months showed partial agenesis of the
corpus callosum and hypoplasia of the orbits. Minimal ocular
tissue  was  noted  in  the  orbit  with  visualization  of  the
extraocular muscles and lacrimal glands. The optic nerves
were not visualized. The maxillae were hypoplastic.
At approximately nine months, she began treatment with
thyroid supplementation for hypothyroidism. She is of a low
growth percentile with normal growth hormone levels. She
had urticaria pigmentosa at 14 months of age. At the age of
16 months, she sat without support, rolled, and babbled with
consonants and vowels. She finger feeds and has no feeding
difficulties. Her development is delayed but is more advanced
than that of her sister, the proband, at the equivalent age. The
mother  has  normal  vision  and  an  unremarkable
ophthalmologic examination. She has normal motor abilities
and  intellect.  A  head  MRI  scan  of  the  mother  was
unremarkable.
Sequence analysis detected two alleles in the proband, the
affected sibling, and the clinically normal mother (54B). One
allele was the wild type sequence and the other was a c.
549delC (p.Pro184ArgfsX19) in the coding sequence (Figure
3B). The deletion changes the reading frame and results in a
premature  stop  codon  19  amino  acids  downstream  of  the
deletion site. The mutation is predicted to delete part of the
COOH-terminal activation domain and to produce a truncated
peptide (Figure 3C). The father (54C) of the proband was
homozygous for the wild type allele.
Patient  49A  is  a  17-year-old  female  with  bilateral
anophthalmia.  Her  clinical  features  include  a  ventricular-
septal defect, which resolved without surgical intervention,
and fusion of two primary teeth of the left lower jaw. She is
developmentally normal and is currently applying to four-year
colleges.  The  parents  were  unaffected.  A  heterozygous
sequence variant was identified in this individual in the 3′-
UTR by CSGE (Figure 4A). Sequence analysis detected two
alleles,  one  with  a  wild  type  sequence  and  one  with  a
nucleotide  substitution,  c.*557G>A  (Figure  4B).  The
sequence alteration does not predictably change the SOX2
protein and is not a previously described SNP (dbSNP Build
128).  A  review  of  transcription  factor  databases  did  not
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586uncover  known  regulatory  elements  associated  with  the
nucleotide substitution. DNA was unavailable from additional
unaffected family members of the proband.
Figure 3. Mutation in the SOX2 activation domain. Genomic DNA
from affected patients, unaffected relatives, and healthy controls are
amplified by PCR. PCR products are separated by electrophoresis in
an  8%  polyacrylamide  gel  for  detection  of  heteroduplexes  and
homoduplexes.  Genomic  DNA  samples  are  then  sequenced  for
detection of sequence variants. A: Heteroduplexes detected by CSGE
is shown. Lanes C1 and C2 represent the healthy controls; Lane 54A
represents  the  proband;  Lane  54B  represents  the  mother  of  the
proband; Lane 54C represents the father of the proband; and Lane
54H represents the affected sibling of the proband. The additional
slower  band  in  patient  54A  may  represent  a  conformational
intermediate  formed  during  gel  electrophoresis,  resulting  in  a
different mobility compared to homoduplexes and the triplet. B:
Sequence analysis shows two alleles in the proband 54A, the affected
sibling 54H, and the clinically normal mother 54B. One allele is the
wild type sequence and the other one is single nucleotide deletion at
c.549delC. The father 54C is homozygous for the wild type allele.
C: The single nucleotide deletion at c.549delC results in a frame shift
mutation and premature termination at 19 amino acids downstream
of the deletion site (p.Pro184ArgfsX19). The mutation is predicted
to delete part of the C-terminal activation domain and to produce a
truncated peptide.
To determine that the above sequence alterations detected
in anophthalmia and microphthalmia patients were not single
nucleotide  polymorphisms  (SNPs),  80  healthy  control
individuals  were  examined  by  direct  sequencing  analysis.
None of the above sequence alterations were found in the
normal  control  subjects.  During  this  screening,  we  also
detected SNP c.*469 C>A in 2 out of 34 patients. The SNP is
a known variant and located at 3′ UTR (SNP rs11915160).
To evaluate sequence variations in CHX10, the same
cohort  of  patients  were  screened  by  CSGE  and  direct
sequencing.  The  majority  of  sequence  variations  were
detected  in  exon  3  (Table  2),  and  the  mutations  were  all
synonymous, c.471 C>T (p.Ser157Ser, rs35435463) and c.
579  G>A  (p.  Gln193Gln,  novel  SNP).  Another  sequence
variation was found in exon 5, c.871 G>A (p. Asp291Asn,
novel SNP), in one affected individual resulting in a non-
synonymous polymorphism. Using healthy controls, the same
sequence variant was found, suggesting non-causality.
DISCUSSION
The present study identified two novel mutations and two
sequence variants (one novel, one known SNP) in SOX2 in 6
(two  siblings)  out  of  34  anophthalmia/microphthalmia/
coloboma patients. The frequency of mutations in SOX2 in
anophthalmia  and  microphthalmia  patients  is  estimated  at
Figure 4. SOX2 mutation in the 3′- untranslated region (3′-UTR).
Genomic DNA from the affected patient and healthy controls are
amplified by PCR. PCR products are separated by electrophoresis in
an  8%  polyacrylamide  gel  for  detection  of  heteroduplexes  and
homoduplexes.  Genomic  DNA  samples  are  then  sequenced  for
detection of sequence variants. A: Heteroduplexes detected by CSGE
is shown. Lanes C1 and C2 represent the healthy controls and Lane
49A  represents  the  proband.  Sample  from  patient  49A  shows
heteroduplex comparing to homoduplex observed in samples from
normal  controls  (C1  and  C2).  B:  A  nucleotide  substitution  at
c.*557G>A of the 3′-UTR is identified in patient 49A, but not in
normal  controls  (C).  The  sequence  variant  does  not  predictably
change the SOX2 protein and is not a previously described SNP.
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58710% for this study, which is consistent with previous reports
[4,14,19]. A mutational analysis of CHX10 of the same cohort
of  anophthalmia/microphthalmia  patients  identified  two
synonymous  sequence  variants  in  exon  3  and  one  non-
synonymous  sequence  variant  in  exon  5.  The  non-
synonymous  polymorphism  was  also  present  in  normal
controls,  suggesting  it  is  not  causative.  Further  sequence
analysis of other genes associated with anophthalmia and
microphthalmia  such  as  PAX6  [7,25],  BCOR  [26],  OTX2
[27], SIX6 [28,29], and CHD7 [30,31] is ongoing in this study
cohort to determine mutation associations.
Two mutations, a nonsense mutation and a frameshift
mutation, were located in the coding region of SOX2, and both
resulted in truncation of the SOX2 protein. The shortened
protein  product  may  result  in  loss  of  function.  In  animal
studies, homozygous mice for SOX2 null allele are embryonic
lethal [16] and heterozygous mice with one null allele are
normal  compared  to  that  of  the  wild  type  [32].  Further
TABLE 2. SEQUENCE VARIATIONS IN CHX10.
Person ID Exon 3 Sequence results Exon 5 Sequence results
012A homoduplex homoduplex
013A homoduplex homoduplex
018A heteroduplex c.471 C>T (p.S157S) homoduplex
023A homoduplex homoduplex
023I homoduplex homoduplex
025A heteroduplex c.471 C>T (p.S157S) homoduplex
027A heteroduplex c.471 C>T (p.S157S) homoduplex
029A heteroduplex c.471 C>T (p.S157S) homoduplex
030A heteroduplex c.471 C>T (p.S157S) homoduplex
031A heteroduplex c.471 C>T (p.S157S) homoduplex
033A homoduplex homoduplex
034A homoduplex homoduplex
035A heteroduplex c.471 C>T (p.S157S) homoduplex
037A homoduplex homoduplex
038A homoduplex homoduplex
040A homoduplex homoduplex
041A homoduplex homoduplex
042A heteroduplex c.471 C>T (p.S157S) homoduplex
043A heteroduplex c.471 C>T (p.S157S) homoduplex
044A homoduplex homoduplex
045A homoduplex homoduplex
046A homoduplex homoduplex
047A homoduplex homoduplex
048A homoduplex homoduplex
049A heteroduplex c.579 G>A (Q193Q) homoduplex
050A homoduplex homoduplex
051A homoduplex homoduplex
052A homoduplex homoduplex
053A heteroduplex c.471 C>T (p.S157S) homoduplex
054A homoduplex homoduplex
054H heteroduplex c.471 C>T (p.S157S) homoduplex
055A homoduplex heteroduplex c.871 G>A (p.D291N)*
056A homoduplex homoduplex
058A homoduplex homoduplex
059A heteroduplex c.471 C>T (p.S157S) homoduplex
061A homoduplex homoduplex
All sequence variations detected in CHX10 were in exons 3 and 5. Homoduplex indicates two identical alleles. Heteroduplex
indicates different alleles. One allele is the wild type sequence and the other one is a sequence variant differing from the wild
type one. The single nucleotide substitution at c.471 C>T is a known SNP (rs35435463) and results in a synonymous change
in the protein sequence (p.Ser157Ser). The single nucleotide substitution at c.579 G>A is a novel SNP and results in a
synonymous change in the protein sequence (p. Gln193Gln). Another novel sequence variation, c.871 G>A, is identified in exon
5 in one affected individual and results in a non-synonymous change in the protein sequence (p. Asp291Asn). This sequence
variation  is  also  identified  in  healthy  controls.  G=guanosine,  T=thymidine,  C=cytidine,  A=adenosine,  S=Ser=serine,
Q=Gln=glutamine, D=Asp=aspartic Acid, N=Asn=asparagine. The asterisk indicates that the heteroduplex is detected in 4 of
50 healthy control samples.
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588reduction of the level of SOX2 expression by deleting a neural
cell-specific enhancer on a heterozygous background resulted
in  reduced  viability  and  neurodegeneration  [32].  These
observations  suggest  that  the  abnormal  phenotype  may
become apparent when SOX2 expression falls below a certain
threshold, or loss of function in one allele reduces SOX2
expression below that level. One of the mutations detected in
this  study  was  at  the  3′  UTR.  Although  the  relationship
between  the  mutation  at  the  3′-UTR  and  anophthalmia/
microphthalmia is indeterminate, one possibility is that the
nucleotide  substitution  at  c.*557G>A  affects  SOX2
expression.  This  is  supported  by  the  observation  that  the
3′UTR of SOX2 contains regulatory elements that enhance its
transcriptional activity in embryonic stem cells [33].
Of interest is the transmission of a SOX2 mutation from
an unaffected mother to her two daughters in the example of
sibling  patients  54A  and  54H.  Gonosomal  mosaicism,
evidenced by the presence of a mutation in buccal cells but
not in white cell-derived DNA, has been reported for SOX2 in
an  unaffected  parent  [34].  We  were  able  to  identify  this
mutation in genomic DNA derived from white blood cells in
the unaffected mother. This suggests that this mother may not
be  mosaic  in  this  circumstance.  We  propose  that  the
anophthalmia phenotype appears to be non-penetrant. Non-
penetrant mutations have been reported previously in sonic
hedgehog (SHH) [34] and in fibroblast growth factor receptor
1 (FGFR) [35]. This example underscores the importance of
testing  seemingly  unaffected  parents  once  a  mutation  is
discovered in their offspring regardless of their phenotype and
points out that some individuals with a SOX2 mutation may
be non-penetrant.
Our patients with coding region mutations had SOX2
phenotypes consistent with previous studies [4,10-12]. All
patients  with  mutations  had  bilateral  anophthalmia  and
unilateral severe microphthalmia (40A, 49A, 54H) with the
exception of patient 54A who had unilateral anophthalmia
instead of bilateral anophthalmia. This suggests that SOX2
mutations  cause  a  more  severe  disruption  of  normal  eye
development and that microphthalmia/anophthalmia are of a
spectrum  of  the  same  disease.  The  patients  with  coding
sequence  mutations  (40A,  54A,  and  54H)  had  significant
brain abnormalities. Patient 40A showed dilated ventricles
and microcephaly. Patient 54A was diagnosed with a right
middle fossa arachnoid cyst and partial absence of posterior
aspect of corpus callosum including the splenium. Patient
54H, the sibling of patient 54A, had partial agenesis of the
corpus callosum. Brain structure changes are also consistent
with other studies and are supported by murine models of
SOX2 deficiency with neurodegeneration and impaired brain
neurogenesis  [32].  Hormonal  deficiencies  and  growth
retardation are also important phenotypic associations with
SOX2 coding sequence changes (patients 40A, 54A, and 54H).
Ragge  et  al.  [10]  have  reported  a  case  of  anophthalmia/
microphthalmia caused by a frameshift mutation in SOX2
(case 9, c.628delA, p.Met210fs211X). The genetic location of
that mutation is similar to the proband 54A and her sibling
54H  (c.549delC,  p.Pro184ArgfsX19)  in  this  study.  The
neurological  phenotypes  in  this  study,  including  brain
malformations and seizure activity, were also present in their
case [10]. Patient 49A with a 3′-UTR mutation had a cardiac
ventricular-septal  defect  with  dental  anomalies.  Different
forms of craniofacial and dental defects were also noted in
some patients with coding region mutations of SOX2 gene.
Patient 54A (Appendix 1) had facial asymmetry and small,
widely spaced teeth. One of the patients (case #1) reported by
Ragge et al. [10] also showed craniofacial dysmorphisms and
widely spaced teeth. The SOX2 UTR mutations appear to be
associated with severe eye development but are perhaps less
likely to manifest with neurological manifestations.
In conclusion, this study confirms that heterozygous loss
of  function  mutations  in  SOX2  cause  anophthalmia  and
microphthalmia and represent approximately 10% of patients
ascertained for anophthalmia and microphthalmia but may
also be non-penetrant. Mutations in CHX10 are less frequently
found. Genetic screening of other candidate genes and the
identification of genetic factors influencing SOX2 expression
may help to determine the susceptibility of various disease
alleles  in  the  occurrence  of  this  severe  form  of  eye
malformation  and  also  help  to  identify  factors  that  may
influence  SOX2  expression.  Further  characterization  of
genetic interactions among causative genes may also help to
further our understanding of the formation of the eye.
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591Appendix 1. Patient demographics and mutations and sequence variants in
SOX2 and CHX10 genes.
To access the data, click or select the words “Appendix
1”. This will initiate the download of a compressed (.zip)
archive  that  contains  the  file.  This  file  should  be
uncompressed with an appropriate program (the particular
program will depend on your operating system).
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